Skip to content
EPSpeak
Download

About EPSpeak and MANOAI Pty Ltd

EPSpeak is made by MANOAI Pty Ltd in Perth and developed by clinicians working in psychiatry, drawing on published research into medication side effects.

Built on evidence, designed for people

At its heart, EPSpeak is about making health information feel less complicated and more approachable, helping people better understand their medications, symptoms and experiences without feeling alone in their treatment journey.

EPSpeak was developed by clinicians working in psychiatry, alongside published research comparing how different medications affect movement.

The research behind the risk profiles

The medication side-effect risk profiles in the app are drawn from published comparative research, not from a single opinion. These are the sources.

  1. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysisHuhn M, Nikolakopoulou A, Schneider-Thoma J, et al. The Lancet. 2019.

    Comparative tolerability across antipsychotic medicines, including movement-related side effects.

  2. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysisLeucht S, Cipriani A, Spineli L, et al. The Lancet. 2013.

    Earlier comparative tolerability data that the movement side-effect rankings build on.

  3. The Maudsley Prescribing Guidelines in Psychiatry, 14th editionTaylor DM, Barnes TRE, Young AH. Wiley Blackwell. 2021.

    The standard reference work used to sense-check how the profiles describe each class.

  4. Anticholinergic activity of 107 medications commonly used by older adultsChew ML, Mulsant BH, Pollock BG, et al. Schizophrenia Research. 2006.

    The anticholinergic component of the three-part risk profile.

The people behind EPSpeak

EPSpeak was developed by clinicians working in psychiatry, together with research into artificial intelligence and psychiatry. These are the people involved.

  • Dr Alistair James Carroll

    Senior Psychiatry Registrar, advanced trainee in forensic psychiatry

    A doctor in specialist psychiatry training, and one of the clinicians EPSpeak was developed with.

    AHPRA registration: MED0001186519

  • Erandi Liyanage

    PhD candidate in artificial intelligence and psychiatry

    A researcher at the University of Technology Sydney whose doctoral work sits where artificial intelligence meets psychiatry.

    University of Technology Sydney

Breaking the stigma

EPSpeak is on a mission to help reduce the stigma around living with treatment-resistant depression, schizophrenia and bipolar disorder.

We believe people deserve to understand their health, feel comfortable asking questions, and have a voice in conversations about their treatment.

Your health journey is your story. EPSpeak helps you understand it, keep track of it, and share it when you're ready.

MANOAI Pty Ltd

Capital Square Towers, Level 25, Tower 3, 1 Spring Street
Perth WA 6000
Australia

info@epspeak.co
ABN
48 689 793 244
ACN
689 793 244

EPSpeak is a medication and symptom companion for people taking antidepressant or antipsychotic medication.

MANOAI Pty Ltd

What are extrapyramidal symptoms (EPS)?

EPS are movement side effects of some antipsychotic and antidepressant medicines: tremor, akathisia, stiffness and slowness. Signs, causes and what to do.

What are extrapyramidal symptoms (EPS)?

The research behind the risk profiles